Immuneering IMRX 深 沪
等待开盘 09-28 09:30:00 美东时间
4.27
-0.070
-1.61%
华盛通- 最 高4.40
- 今 开4.36
- 成交量 51.35万股
- 最 低 4.255
- 昨 收 4.34
- 总市值 2.76亿
- 52周最高 8.48
- 市盈率 静 --
- 换手率 0.79%
- 52周最低 3.86
- 委 比 -0.22%
- 总股本 6469.74万
- 历史最高 33.99
- 量 比 0.77
- 振 幅 3.34%
- 历史最低 1.00
- 每 手 1
- 风险率 0.90%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Immuneering to Present at the ESMO Congress 2026
<p>Immuneering Corporation announced that an abstract on its Phase 3 MAPKeeper 301 trial of atebimetinib combined with modified gemcitabine/nab-paclitaxel (mGnP) for first-line pancreatic cancer treatment has been accepted for a poster presentation at the ESMO Congress 2026 in Madrid. The trial aims to evaluate the efficacy and safety of this combination in patients with metastatic pancreatic ductal adenocarcinoma. Full abstracts will be availabl...
09-24 11:30
Immuneering To Present Data At American Association For Cancer Research Conference On Pancreatic Cancer: New Frontiers In Biology And Therapeutic Development
Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced it will present a poster at the American Association for Cancer Research (AACR) Conference on Pancreatic Cancer: New Frontiers in Biology a...
09-10 19:32
Immuneering to Participate in Upcoming Investor Conferences
Immuneering Corporation announced that its management will participate in two upcoming investor conferences: the Cantor Global Healthcare Conference on September 10, 2026, and the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026. Both events will feature fireside chats and 1x1 investor meetings, with webcasts available on Immuneering’s website. The company focuses on developing innovative cancer treatments, including...
09-03 20:05
Immuneering Highlights Atebimetinib’s Potential In 1L Metastatic Pancreatic Cancer As FDA Approves New 2L Treatment
Immuneering Highlights Atebimetinib’s Potential In 1L Metastatic Pancreatic Cancer As FDA Approves New 2L Treatment
08-27 05:20
Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients
FDA approves a new second-line treatment for metastatic pancreatic cancer. Immuneering's atebimetinib is in a global Phase 3 trial (MAPKeeper 301) for first-line patients. Previously, the Phase 2a study showed a 17.3-month median overall survival with minimal severe side effects. The trial prioritizes patient well-being and minimal side effects.
08-26 21:16
This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Stifel analyst Stephen Willey initiated coverage on Lyell Immunopharma Inc (NASDAQ:LYEL) with a B...
08-06 22:12
Immuneering GAAP EPS of -$0.27 in-line
Immuneering press release (IMRX): Q2 GAAP EPS of -$0.27 in-line. Ended Q2 2026 with $182.7 million in cash, cash equivalents and marketable securities with anticipated runway into 2029 More on Immunee...
08-05 19:43
Immuneering Q2 EPS $(0.27), Inline
Immuneering (NASDAQ:IMRX) reported quarterly losses of $(0.27) per share which met the analyst consensus estimate. This is a 32.5 percent increase over losses of $(0.40) per share from the same period last year.
08-05 19:38
Publication in Cancer Research Details Atebimetinib’s Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition
Atebimetinib, a novel MEK inhibitor, demonstrates broad antitumor activity across KRAS-, NRAS-, and BRAF-mutant models, including colorectal, lung, and melanoma cancers, by resisting RAF-mediated bypass signaling. In head-to-head studies, it showed deeper and more durable tumor growth inhibition compared to binimetinib. Preclinical models indicated favorable tolerability, with atebimetinib-treated animals maintaining body weight better than untre...
07-21 20:05
美股大行评级 | 伯恩斯坦上调Robinhood目标价从130美元升至160美元；纽约梅隆银行、Datadog、五三银行、旅行者财产险集团获多家机构上调评级
今日重点评级关注：Needham：维持Immuneering"买入"评级，目标价从11美元升至18美元；富瑞：维持塞德斯医疗"买入"评级，目标价从90美元升至100美元
07-21 11:36
